uniQure (NASDAQ:QURE – Get Rating) had its target price reduced by Wells Fargo & Company from $24.00 to $14.00 in a research report released on Thursday morning, The Fly reports. QURE has been the subject of a number of other research reports. UBS Group dropped their price objective on shares of uniQure from $45.00 to […]
uniQure (NASDAQ:QURE – Get Rating) had its target price cut by Wells Fargo & Company from $24.00 to $14.00 in a research report released on Thursday morning, The Fly reports. QURE has been the topic of a number of other research reports. UBS Group lowered their target price on uniQure from $45.00 to $42.00 in […]
uniQure (NASDAQ:QURE – Get Rating) CFO Christian Klemt sold 1,587 shares of the stock in a transaction on Friday, June 16th. The stock was sold at an average price of $18.94, for a total transaction of $30,057.78. Following the sale, the chief financial officer now directly owns 132,854 shares in the company, valued at $2,516,254.76. […]
Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL BehringLEXINGTON, Mass. and AMSTERDAM, June 20, 2023 uniQure N.V. , a leading gene therapy company advancing. | June 20, 2023
uniQure (NASDAQ:QURE – Get Rating) was the recipient of some unusual options trading on Tuesday. Stock investors purchased 4,813 call options on the company. This is an increase of 407% compared to the typical volume of 949 call options. Hedge Funds Weigh In On uniQure A number of large investors have recently made changes to […]